Cue Biopharma Inc V.CUE

Primary Symbol: CUE

Healthcare Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

NDAQ:CUE - Post by User

Cue Biopharma Inc

<< Previous

Bullboard Posts

Next >>

Post by nokiawatchon Jan 07, 2011 5:03pm

411 Views

Post# 17941363

Quiet board will wake up soon with news

I for one have been sitting back and adding to my position from time to time as I did today. CUE is still very much undervalued vs the already over 10 million proven lbs Uranium. To my suprise CUE is still one of those unknown prospects in Stealth Stage that certainly has huge potentail for profit. The deposit is there and when the goods are exposed, this puppy will fly! The Uranium cycle begins .
GLTA

<< Previous

Bullboard Posts

Next >>

FLYHT and WestJet partner on weather forecasting